Skyrizi for Psoriasis

Skyrizi (risankizumab-rzaa) joins the ever-growing ranks of biologics for the treatment of psoriasis. Skyrizi is new IL-23 inhibitor, which binds to the p19 subunit,  joining Tremfya and Ilumya, and Stelara (which binds to the p40 subunit).  It is approved for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy of phototherapy. Skyrizi has… Read More

Risks For Basal Cell Carcinoma Skin Cancer

Basal cell carcinoma (BCC) is the most common cancer worldwide. In the United States, the lifetime risk of developing BCC is estimated to be around 20%, and 30% in whites. It is the most common skin cancer seen by most dermatologists. Although many things in life are out of our control, there are some risk… Read More